Third-Line and Beyond Rovalpituzumab Tesirinen in DLL3-Expressing, Relapsed/ Refractory Small-Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients With DLL3-Expressing, Relapsed/ Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
Clin. Cancer Res 2019 Sep 10;[EPub Ahead of Print], D Morgensztern, B Besse, L Greillier, R Santana-Davila, N Ready, CL Hann, BS Glisson, AF Farago, A Dowlati, CM Rudin, S Le Moulec, S Lally, S Yalamanchili, J Wolf, R Govindan, DP CarboneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.